Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.coviro.2021.03.008 http://scihub22266oqcxt.onion/10.1016/j.coviro.2021.03.008 33906124!8065267!33906124     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33906124&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Curr+Opin+Virol 2021 ; 48 (?): 65-72 Nephropedia Template TP {{tp|p=33906124|t=2021. Future considerations for the mRNA-lipid nanoparticle vaccine platform |pdf=|usr=}}{{33906124}} gab.com Text Future considerations for the mRNA-lipid nanoparticle vaccine platform JO: Curr Opin Virol http://www.kidney.de/pget.php?&tw=1&pmid=33906124 #FOAvip Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Kariko and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology. Twit Text FOAVip Future considerations for the mRNA-lipid nanoparticle vaccine platform ????Curr Opin Virol http://www.kidney.de/pget.php?&tw=1&pmid=33906124 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33906124 #FOAvip English Wikipedia <ref>{{Cite pmid|33906124}}</ref> Future considerations for the mRNA-lipid nanoparticle vaccine platform #MMPMID33906124 Igyarto BZ; Jacobsen S; Ndeupen S Curr Opin Virol 2021[Jun]; 48 (?): 65-72 PMID33906124show ga Vaccines based on mRNA-containing lipid nanoparticles (LNPs) pioneered by Katalin Kariko and Drew Weissman at the University of Pennsylvania are a promising new vaccine platform used by two of the leading vaccines against coronavirus disease in 2019 (COVID-19). However, there are many questions regarding their mechanism of action in humans that remain unanswered. Here we consider the immunological features of LNP components and off-target effects of the mRNA, both of which could increase the risk of side effects. We suggest ways to mitigate these potential risks by harnessing dendritic cell (DC) biology. |*Lipids/administration & dosage/immunology[MESH] |*Nanoparticles/administration & dosage/metabolism[MESH] |*RNA, Messenger/administration & dosage/immunology[MESH] |COVID-19 Vaccines/immunology[MESH] |COVID-19/prevention & control[MESH] |Dendritic Cells/*immunology[MESH] |Humans[MESH] |Immunization/*methods[MESH]Future considerations for the mRNA-lipid nanoparticle vaccine platform(epmc).pdf DeepDyve Pubget Overpricing